Novartis Acc company information, Employees & Contact Information

Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline Novartis

Novartis Fabhalta® (iptacopan) meets Phase III primary endpoint, slows kidney function decline in patients with IgA nephropathy (IgAN) Novartis

Novartis Kisqali® 5-year NATALEE data demonstrate 28% reduction in risk of recurrence in the broadest early breast cancer patient population Novartis

Novartis to Acquire Avidity Biosciences for US$12 Billion in Rare-Disease Push PharmiWeb.com

Novartis Enters $12 Billion Definitive Merger Agreement to Acquire Avidity Biosciences Pharmaceutical Executive

Novartis to buy Avidity Biosciences in $12B deal to boost rare disease pipeline (NVS:NYSE) Seeking Alpha

Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD) Novartis

FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer Novartis

Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024 Novartis

Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer Novartis

Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU) Novartis

Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis Novartis

Novartis in Society Integrated Report 2024 Novartis

Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront Novartis

New Novartis Phase III data demonstrate meaningful efficacy and safety results of intrathecal onasemnogene abeparvovec in broad patient population with SMA Novartis

Novartis appoints Mukul Mehta as Chief Financial Officer, as Harry Kirsch retires after 22 years with the company Novartis

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Novartis

New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline Novartis

Novartis continues strong momentum with double-digit sales growth, robust margin expansion and multiple approvals in Q1 Novartis

Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN) Novartis

Tina’s Story: One Woman’s Burden of Living With Sjogren's Disease Novartis

The 2025 Eurovision Song Contest Novartis

Elizabeth McNally, M.D., Ph.D. Novartis

New Phase IIIB data shows Novartis Fabhalta® improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from anti-C5 therapy Novartis

Addressing unmet needs for inherited neuromuscular diseases Novartis

Our commitment to ethical and responsible use of Artificial Intelligence (AI) Novartis

Novartis ranks first in 2024 Access to Medicine Index Novartis

Immunology disease research at Novartis Novartis

Managed access programs Novartis

Compassionate use: Providing access to much needed treatments Novartis

Targets Novartis

Oncology research at Novartis Novartis

Therapeutic areas Novartis

FDA approves Novartis Vijoice® (alpelisib) as first and only treatment for select patients with PIK3CA-Related Overgrowth Spectrum (PROS) Novartis

Research and development Novartis

About Novartis

Payments to Healthcare Professionals Novartis

FDA approves Novartis Kesimpta® (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis Novartis

From black holes to AI driven drug discovery – collaboration wins the day Novartis

Human rights Novartis

Novartis delivers strong sales growth, robust margin expansion and major innovation milestones. Raises FY guidance Novartis

Sub-Saharan Africa Novartis

Novartis data show potential of remibrutinib as an oral treatment for chronic spontaneous urticaria providing significant symptom improvement as early as Week 2 Novartis

People and culture Novartis

Climate Novartis

Novartis builds on neuroscience pipeline and xRNA platform capabilities with acquisition of DTx Pharma Novartis

FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer Novartis

Novartis enters agreement to acquire Mariana Oncology, strengthening radioligand therapy pipeline Novartis

Coronavirus Novartis

US Biomedical Research internship programs Novartis

Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN) Novartis

Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH Novartis

Novartis commitment to patients and caregivers Novartis

Sickle cell disease Novartis

Early careers Novartis

ESG rating performance Novartis

Board of Directors Novartis

Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand therapy manufacturing facility in Indianapolis Novartis

Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors Novartis

Novartis presents new data on safety and efficacy of Zolgensma, including maintained and improved motor milestones in older and heavier children with SMA Novartis

Negative impact of the IRA on patient access to innovative treatments Novartis

Novartis bolsters innovative medicines strategy and renal pipeline with agreement to acquire Chinook Therapeutics for USD 3.2bn upfront (USD 40 / share) Novartis

Novartis Cosentyx® positive 16-week PREVENT results advance potential new indication for patients with axial spondyloarthritis Novartis

AveXis Announces Innovative Zolgensma® Gene Therapy Access Programs for US Payers and Families Novartis

Novartis delivers strong sales growth, robust margin expansion and raises guidance. Announces USD 15 billion share buyback and Board endorses Sandoz spin-off¹˒² Novartis

European Medicines Agency (EMA) approves safety label update for Novartis Beovu® Novartis

Robots speed the pace of modern drug discovery Novartis

Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis Novartis

Novartis Cosentyx® gains positive CHMP opinion for hidradenitis suppurativa Novartis

Learning and engagement Novartis

Novartis to acquire The Medicines Company for USD 9.7 bn, adding inclisiran, a potentially transformational investigational cholesterol-lowering therapy to address leading global cause of death Novartis

Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML Novartis

Novartis to acquire Gyroscope Therapeutics, adding a one-time gene therapy that could transform care for geographic atrophy, a leading cause of blindness Novartis

Novartis data show rapid and effective disease activity control with remibrutinib (LOU064) in patients with chronic spontaneous urticaria Novartis

Nature - Water Novartis

Novartis announces positive result of phase III study with radioligand therapy 177Lu-PSMA-617 in patients with advanced prostate cancer Novartis

Novartis renews commitment to malaria elimination, investing USD 100 million to research and develop next-generation antimalarials Novartis

Novartis receives EU approval for Leqvio®* (inclisiran), a first-in-class siRNA to lower cholesterol with two doses a year Novartis

Translational medicine research at Novartis Novartis

Novartis key multiple sclerosis product Gilenya® approved in China Novartis

Product sales Novartis

Machine learning poised to accelerate drug discovery Novartis

Global Health disease area research at Novartis Novartis

Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and statistically significant proteinuria reduction in patients with C3 glomerulopathy (C3G) Novartis

Dividend information Novartis

Novartis acquires Arctos Medical, expanding optogenetics portfolio to bring gene therapies to patients with severe vision loss Novartis

Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease Novartis

US FDA approves updated Novartis Beovu® label, to include additional safety information Novartis

Novartis announces collaboration with Molecular Partners to develop two DARPin® therapies designed for potential use against COVID-19 Novartis

Novartis announces lift of partial clinical trial hold and plans to initiate a new, pivotal Phase 3 study of intrathecal OAV-101 in older patients with SMA Novartis

Novartis Tafinlar® (dabrafenib) + Mekinist® (trametinib) demonstrates unprecedented efficacy in pediatric patients with BRAF V600 low-grade gliomas in Phase II/III study Novartis

Novartis continues strong momentum in Q3 with 10% sales growth, 20% core operating income growth, and important innovation milestones; raises FY 2024 guidance Novartis

Novartis expands Zolgensma manufacturing capacity with approval of multi-product North Carolina facility Novartis

Novartis presents new long-term Leqvio® (inclisiran) data demonstrating consistent efficacy and safety beyond six years Novartis

Novartis provides an update on Phase III ligelizumab (QGE031) studies in chronic spontaneous urticaria (CSU) Novartis

Medical congresses and events Novartis

Novartis announces new CEO of Oncology Business Unit Novartis

FDA approves Novartis Scemblix® (asciminib), with novel mechanism of action for the treatment of chronic myeloid leukemia Novartis

Remembering men’s health this National Veterans and Military Families Month Novartis

Novartis commits to donate up to 130 million doses of hydroxychloroquine to support the global COVID-19 pandemic response Novartis